封面
市場調查報告書
商品編碼
2150228

C-MET 和 HGF 抑制劑市場報告:趨勢、預測和競爭分析(至 2035 年)

C-MET & HGF Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2035

出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

C-MET 和 HGF 抑制劑市場

受醫院和藥局市場機會的推動,全球C-MET和HGF抑制劑市場前景光明。預計該市場規模將從2027年的83億美元成長至2035年的491億美元,2027年至2035年的複合年成長率(CAGR)預計為24.8%。市場成長的主要促進因素包括癌症患者數量的增加、對標靶癌症療法的需求日益成長以及對精準醫療的日益重視。

  • 根據 Lucintel 的預測,在藥物類型中,Cabozantinib由於其對多種癌症類型的廣泛療效,預計在預測期內將實現最高的成長。
  • 從應用角度來看,由於醫院癌症治療中引入標靶癌症療法的趨勢,醫院產業預計在預測期內將呈現更高的成長。
  • 從區域來看,由於亞太地區癌症診斷率高,且標靶癌症療法的普及程度不斷提高,預計該地區在預測期內將呈現最高的成長率。

C-MET和HGF抑制劑市場的新趨勢

預計在2025年至2027年間,C-MET和HGF抑制劑將從廣泛的腫瘤學研究階段過渡到高階藥物開發階段。多項資訊來源表明,與其他藥物聯合治療以及伴隨診斷將改善其臨床應用。 Lucintel的報告指出,商業性現實和監管環境的波動將驅動市場發展。

  • 生物標記準確性:在非小細胞肺癌 (NSCLC) 中,MET 14 號外顯子跳躍突變的識別較為常見,FDA 已批准和/或擴大了某些 CML 抑制劑的適應症。這些療法的具體應用將在未來幾年內確定。
  • 選擇性抑制:該領域普遍認為,對c-MET的高選擇性對於治療應用至關重要。雖然許多藥物對c-MET有效,但目前的研究重點是針對其他腫瘤訊號路徑的藥物。
  • 聯合治療:臨床前和臨床數據支持將MET路徑抑制劑與其他路徑抑制劑和化療藥物合併使用。目前正在進行的多項臨床試驗有望進一步提高MET通路抑制劑的臨床效用。
  • 基於安全性的差異化:諸如周邊水腫、胃腸道疾病和肝功能異常等低發生率的副作用仍然會導致治療中斷。各公司正日益關注最佳化藥物的藥理特性。治療中斷次數較少的產品對於慢性疾病適應症尤其具有吸引力。
  • 區域商業化:藥品核准和報銷流程因國家而異。企業會根據這些區域差異,策略性地調整產品上市時間。例如,中國的「2025腫瘤政策」加快了癌症治療藥物在該國的推廣。到2030年,各國不同的證據等級和標準將影響全球產品的市場滲透率和收入來源。

能夠有效且持續抑制靶向MET受體的療法將比使用其他抑制劑更有價值。隨著聯合治療的日益普及,擁有高價值且易於取得的組合產品和伴隨診斷試劑的公司將更具競爭力。針對難治性癌症的重大治療機會和未滿足的醫療需求將推動投資和併購活動。

C-MET和HGF抑制劑市場的最新趨勢

2021年至2025年,受生物標記驅動的臨床試驗完成、合作關係的建立以及監管決策的最終確定等因素推動,C-MET和HGF抑制劑市場活動活性化。 Lucintel預測,2025年至2027年,隨著各公司繼續專注於同種異體受體蛋白酪氨酸激酶(RTK)的研究,該市場將持續成長和發展。然而,在此期間,各公司將採用不同的策略和方法來進一步推動該領域的發展。

  • 監管批准:2025年5月,FDA加速核准terisotuzumab vedotin-tllv(Emrelis)用於治療不可切除和/或轉移性非鱗狀非小細胞肺癌(NSCLC)。 Emrelis是第一個獲得上市許可的抗體藥物複合體(ADC),預計將在未來至少3至5年內提升c-MET檢測領域的關注度和影響力。
  • 生物標記:對於特立妥珠單抗-維多汀-TLLV(Emrelis),FDA批准該藥物時採用了比MET外顯子14跳躍療法更廣泛、更全面的c-MET蛋白表達框架。艾伯維公司報告稱,在大型LUMINOSITY試驗中,總緩解率為35%。 Emrelis的商業性成功取決於診斷和病理框架的標準化和可用性。
  • 聯合治療研發:默克將繼續進行Pembrolizumab合併c-MET路徑相關療法的研究,並在此期間評估了其他聯合治療的研究。例如,已啟動多項試驗評估Pembrolizumab與其他抗癌療法的聯合應用,並與基因泰克合作進行了一項Pembrolizumab聯合抗PD-L1藥物及其他抗癌療法的研究。儘管安全性和有效性最終將決定聯合療法的上市速度,但支持聯合治療應用的證據十分充分,預計將推動該領域的發展。
  • 管線競爭:目前,savolitinib是唯一處於臨床開發階段的MET選擇性抑制劑。因此,其他抗體偶聯藥物(ADC)可能會對其構成競爭。每種療法的定價和報銷政策可能有所不同,而對於攜帶MET 14號外顯子突變的患者,使用選擇性抑制劑還是ADC所帶來的潛在獲益也會有所不同。
  • 生產製造:抗體藥物複合體(ADC)的生產合約激增,類似計畫的資金也在增加。新建大規模ADC生產設施將有助於緩解目前此類產品供應的瓶頸,並改善多種癌症適應症的治療機會。

精準腫瘤學將持續是腫瘤學領域的重要研究方向。此外,Emrelis的核准將加速c-MET抑制劑在特定癌症患者中的應用。 2026年後,重點仍將放在整合多種療法以及穩定地推進相關技術,從而為患者提供安全、可靠且持續的治療。臨床試驗結果將是影響市場佔有率的主要因素。

目錄

第1章:摘要整理

第2章 市場概覽

  • 背景與分類
  • 供應鏈

第3章 市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章 全球C-MET和HGF抑制劑市場:按類型分類

  • 吸引力分析:按類型
  • Cabozantinib
  • Crizotinib
  • 替泊替尼
  • 其他

第5章 全球C-MET與HGF抑制劑市場:依應用分類

  • 吸引力分析:依目的
  • 醫院
  • 藥局

第6章 區域分析

第7章:北美C-MET和HGF抑制劑市場

  • 北美C-MET和HGF抑制劑市場:按類型分類
  • 北美C-MET和HGF抑制劑市場:按應用領域分類
  • 美國C-MET和HGF抑制劑市場
  • 加拿大C-MET和HGF抑制劑市場
  • 墨西哥 C-MET 和 HGF 抑制劑市場

第8章:歐洲C-MET和HGF抑制劑市場

  • 歐洲C-MET和HGF抑制劑市場:按類型分類
  • 歐洲C-MET和HGF抑制劑市場:按應用領域分類
  • 德國市場對C-MET和HGF抑制劑的需求
  • 法國C-MET和HGF抑制劑市場
  • 義大利C-MET和HGF抑制劑市場
  • 西班牙C-MET和HGF抑制劑市場
  • 英國C-MET和HGF抑制劑市場

第9章:亞太地區C-MET和HGF抑制劑市場

  • 亞太地區C-MET和HGF抑制劑市場:按類型分類
  • 亞太地區C-MET和HGF抑制劑市場:按應用分類
  • 中國C-MET和HGF抑制劑市場
  • 印度C-MET和HGF抑制劑市場
  • 日本C-MET和HGF抑制劑市場
  • 韓國C-MET和HGF抑制劑市場
  • 印尼C-MET和HGF抑制劑市場

第10章:C-MET和HGF抑制劑的全球市場

  • 其他地區 C-MET 和 HGF 抑制劑市場:按類型分類
  • 其他地區的 C-MET 和 HGF 抑制劑市場:按應用
  • 中東C-MET和HGF抑制劑市場
  • 南美C-MET和HGF抑制劑市場
  • 非洲C-MET和HGF抑制劑市場

第11章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析
  • 市佔率分析

第12章 機會與策略分析

  • 價值鏈分析
  • 成長機會分析
  • 新趨勢:全球C-MET和HGF抑制劑市場
  • 戰略分析

第13章:價值鏈中關鍵企業的公司概況

  • 競爭分析概述
  • Exelixis
  • Ipsen
  • Pfizer
  • Novartis
  • Takeda
  • Merck KGaA
  • Takeda Pharmaceutical

第14章附錄

C-MET & HGF Inhibitor Market

The future of the global C-MET & HGF inhibitor market looks promising with opportunities in the hospital and drug store markets. The global C-MET & HGF inhibitor market is expected to reach an estimated $49.1 billion by 2035 from $8.3 billion in 2027 with a CAGR of 24.8% from 2027 to 2035. The major drivers for this market are the increasing incidence of cancer cases, the rising need for targeted cancer therapies, and the growing focus on precision medicine approaches.

  • Lucintel forecasts that, within the type category, cabozantinibm is expected to witness the highest growth over the forecast period due to wide efficacy of cabozantinib against several cancer types.
  • Within the application category, hospital is expected to witness higher growth over the forecast period due to trend of hospital-based cancer care to include the use of targeted cancer therapies.
  • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to higher cancer diagnosis rates, and increased access to targeted cancer therapies.

Emerging Trends in C-MET & HGF Inhibitor Market

C-Met & HGFI inhibitors, from 2025 to 2027, are expected to shift from broad oncology research to sophisticated drug development. Improved positions in the clinic through the combination of other agents and companion diagnostics, have been noted by various sources. The Lucintel report maintains that commercial reality and variability of regulation will govern the market.

  • Biomarker Precision: The identification of MET exon 14 skipping mutations in NSCLC is common and the FDA has approved and/or released label expansions for select CML inhibitors. The next several years will determine how these therapies are prescribed.
  • Selective Inhibition: It is generally accepted in the field that high selectivity for c-MET is critical for therapeutic use. There are a number of agents with activity against c-MET, however, the focus is on agents with activity against other tumour pathways.
  • Combination Therapy: Preclinical and clinical data supports the combination of MET pathway inhibitors and other pathway inhibitors and chemotherapeutic agents. There are a number of ongoing clinical trials that will likely improve the clinical utility of MET pathway inhibitors.
  • Safety-led Differentiation: Unrelated adverse effects of peripheral edema and gastrointestinal issues and liver function test abnormalities continue to lead to the discontinuation of therapy. Companies have shifted their focus to optimizing pharmacology. Products with less treatment disruptions will be more attractive, especially for chronic indications.
  • Regional Commercialization: There are country-level variations in drug approvals and reimbursement processes. Companies strategically time product launches according to local variations. For example, the 2025 Oncology policy in China has accelerated local adoption of oncology therapeutics. Varying levels of evidence and different standards across countries will shape the global product uptake and revenue stream until 2030.

The ability of a therapy to effectively and durably block the target MET receptor will become more valuable than the use of surrogate inhibitors. As combination therapies become more common, companies that have valuable and accessible combination products and companion diagnostics, will be more competitive. Important therapeutic opportunities and unmet needs for difficult to treat cancers will support investment and M&A activities.

Recent Developments in the C-MET & HGF Inhibitor Market

Market activity in the C-MET and HGF inhibitor market picked up from 2021 to 2025, with the completion of Biomarker-led trials, entering into partnerships and reaching regulatory decisions. From 2025 to 2027, Lucintel predicts the market will continue to grow and advance, with companies focusing on the same types of receptor tyrosine kinases (RTKs). However, during this time, companies will also advance the field by utilizing different strategies and approaches.

  • Regulatory Approval: In May 2025, the FDA granted Accelerated Approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of non-squamous NSCLC that is un-resectable and/or metastatic. Emrelis is the first antibody drug conjugate to receive marketing authorization, and will likely stimulate the interest and impact the field of c-MET testing for at least the next 3-5 years.
  • Biomarker: In the case of telisotuzumab vedotin-tllv (Emrelis), the FDA approved the drug using a c-MET protein expression frame work, which is broader and encompassing than MET Exon 14 skipping. AbbVie reported that the pivotal LUMINOSITY Trial had an overall response rate of 35%. The commercial success of Emrelis will be dependent on the standardization and availability of testing and pathology frame work.
  • Combination Development: In addition to continuing to study pembrolizumab in combination with c-MET pathway-related interventions, Merck evaluated other combination studies during the period. For instance, they initiated multiple studies to evaluate the use of pembrolizumab in combination with other anti-cancer therapies and also established a collaboration with Genentech for the study of pembrolizumab in combination with anti-PD-L1 and other oncology therapies. While safety and efficacy will ultimately dictate the pace of adoption, the rationale supporting the use of combination therapies is strong and will likely drive the field.
  • Pipeline Competition: Savolitinib is currently the only selective inhibitor of MET that is in clinical development. As such, the competition that this therapy will face is likely to come from other ADCs. Pricing and reimbursement policies will likely differ for each of these therapies, and the potential benefits for patients with MET exon 14 alterations will likely vary based on the selective inhibitor versus ADC.
  • Manufacturing: There has been a proliferation of contracts for the manufacture of Antibody Drug Conjugates, and financing for similar projects has increased. New, larger ADC manufacturing facilities will help ease the current limitations in supply of these products and improve access for various cancer indications.

Precision oncology will remain a distinct area of focus in oncology, and the approval of Emrelis will facilitate the use of c-MET inhibitors for select cancer patients. Beyond 2026, the focus will remain on the integration of multiple therapies and the progressive advancement of technologies to facilitate safe, reliable and continuous care for patients. The outcome of clinical studies will be the main driver for market share.

Strategic Growth Opportunities in the C-MET & HGF Inhibitor Market

The C-MET and HGF inhibitors market has recently gained momentum with improvements in biomarker testing and the elucidation of resistance mechanisms by the biopharmaceutical industry. During the 2024-2026 period, Lucintel anticipates the monopoly situation in the market will improve with the introduction of differentiated regimens, flexible pharmaceutical distribution models, and diagnostic-led indications.

  • Resistance-controlling Combinations: Currently, the most well-advanced resistance-controlling combination is the use of a c-MET inhibitor in conjunction with an EGFR inhibitor for the treatment of patients with non-small cell lung cancer (NSCLC) who have developed resistance to EGFR-targeted therapy. In February 2025, the VISION study of tiptoeing included 313 patients with met exclusion 14 NSCLC. Development of resistance combining inhibitors of receptor tyrosine kinases extends the duration of therapy and protects and/or extends the period of inhibition of receptor tyrosine kinases.
  • Expanded Companion Diagnostics: A greater availability of liquid biopsy tests will aid in the detection of MET gene amplification and other alterations, including MET exon 14, in the presence of an inadequate tumour sample. The FDA reviewed 20 liquid biopsy tests for cancer in January 2025.
  • Premium Oral Formulation: Strong product differentiation is found in tablets that, for example, allow once-a-day dosing. These tablets are more expensive, as less restrictive requirements for food intake before dosing, and fewer required medical supervision, increase the tolerability of the product. In Japan, oncology products exceeded ¥1 trillion in sales in 2025, and products that enhance adherence and address toxicities will take larger portions of the market.
  • Emerging Market Expansion: New product launches in MET inhibitor oncology will occur in newer, growing markets like China, India and Southeast Asia and Latin America. Of these markets, China is most competitive. There were over 5,000 oncology clinical trials sanctioned by the Chinese FDA in 2025. Even so, the cost of clinical development remains high, and local regulatory and clinical environments constrain rapid development.
  • C-MET Inhibitor Combinations: Beyond lung cancers, C-MET inhibitors will be combined with other agents, and additional indications in other cancers will be defined. With 900,000 cases estimated for 2025, liver cancers remain an unmet need, and in combination with other agents, they may be targeted.

Indiscriminate product prescribing will not be the strongest driver for market growth. True breakthroughs will occur with novel ways to integrate diagnostics for personalized oncology products. Strong, strategic alliances will accelerate market access and product commercialization, particularly in oncology.

C-MET & HGF Inhibitor Market Drivers and Challenges

The market for c-met and HGF inhibitors is advancing due to developments in precision oncology, increase in cancer cases, and supportive regulations by authorities. Pharmaceutical companies are interested in the field, and biomarker tests are improving. Cyclic changes in the economy impact the type of oncology treatments that are commercially available. Stringent regulatory authorities are initially approving more biomarker-based therapies. Lucintel is cautiously optimistic about the market.

The factors responsible for driving this market include:

  • Growing Precision Oncology Demand: An increasing demand for precision oncology has led to the identification of various cancer cases due to c-met pathway activation. It has been observed that tumors overexpressing c-met are often unresponsive to various anti-EGFR therapies. Various pharmaceutical companies have shown interest in developing anti-c-met therapies. The U.S. FDA granted accelerated approval to telisotuzumab vedotin for select cases of non-small cell lung cancer in May 2025. This favorable regulatory decision is expected to stimulate the use of c-met targeted therapies in various cancers. It is expected that in the next 5 years, targeted therapies against the c-met pathway will be used to treat gastric, liver, and other cancers.
  • Improvements in Technology: The development of more effective small-molecule inhibitors and antibody-based platforms may allow the blocking of c-MET and HGF pathways. Innovations in antibody-drug conjugates and bispecific antibodies may facilitate the development of more potent and efficacious therapies against resistant tumors. Examples of advancements in this area include the U.S. FDA's approval of telisotuzumab vedotin in May 2025. In the next 3 to 5 years, more potent therapies, including combination therapies, may be developed, particularly against cancers for which effective treatments are lacking. Additionally, ongoing studies may facilitate the development of therapies against cancers of high unmet medical need and provide response data for cancers for which c-MET and HGF pathways are activated.
  • Positive Changes in Drug Development: Improvements in the U.S. Food and Drug Administration's (FDA) and other regulatory agencies' policies and frameworks to allow for the approval of therapies based on tumour or cellular pathway biomarkers may facilitate access to new treatments for cancers for which effective therapies are lacking. The FDA's May 2025 approval of telisotuzumab vedotin, based on the drug's potential clinical benefit for the treatment of Hodgkin lymphoma, set a precedent for the regulatory approval of novel therapies against cancers of high unmet medical need. More flexible regulatory policies to facilitate and speed up the development of therapies against cancers of high unmet medical need will likely occur in the next 3 to 5 years.
  • Integrative Therapy Approaches: The development of integrative therapies to address resistance to single-agent c-MET or HGF inhibitors is rapidly progressing. Evidence suggests that c-MET or HGF inhibitors may be combined with several other modalities including immunotherapy, chemotherapy, and other kinds of targeted therapy. By 2025, a number of clinical trials evaluated the safety and preliminary activity of c-MET-directed therapies in combination with other agents. It is expected that combining therapies targeted to c-MET will continue to be evaluated to determine the effectiveness of combinations to control more recalcitrant cancers.
  • Industry Competition and Research: The presence of many competing companies has led to significant research and development of more effective and less toxic c-MET and HGF inhibitors. In 2025, the first c-MET-targeted antibody drug conjugate was approved in the U.S. Anticipate that, in the next 5 years, further research and the development of improved methods for the synthesis and clinical trials of oncology therapies will lead to the rapid introduction of new pharmaceutical products, enhanced company revenues and market expansion. Companies will have to develop and market therapies that improve patient outcomes to remain competitive.

The challenges facing this market include:

  • Clinical Resistance & Tumour Heterogeneity: C-MET signaling pathway abnormalities occur in different ways in various patients, and tumour cells can turn to other signaling pathways for survival and proliferation. Due to this reason, in 2025, the focus of the clinical studies were the patient populations in which the MET alterations were defined. However, there are other ways in which the MET pathway can be activated and overexpressed, and choosing the right patients among all these variations is challenging. During the process of developing the therapy for MET alterations, it is likely that resistance is developed to that particular therapy, and in such cases, it is likely that combination or sequential therapy will be pursued.
  • Safety & Tolerability: C-met and HGF inhibitors are likely to have adverse effects like edema and changes in blood and liver functions. Antibody drug conjugates used for inhibiting c-met can have additional adverse effects. Due to the nature of the therapy and the complexity of patient selection, control, and management, there will be strong competition among the available therapies for oncology.
  • Intensive Development and Barriers To Market Access: High costs and restricted market access negatively impact the development of oncology therapies. Regulatory improvements in 2025 enhanced the approvals process, but most of these authorizations were conditional and led to the establishment of post-marketing requirements to generate additional evidence. During the next three to five years, it is expected that the therapies will encounter reimbursement and market access limitations due to the availability of other therapies, including established competitors.

In the case of oncology therapies targeting MET, marketing authorization will be granted only if the therapy meets an unmet need. A meaningful improvement in clinical outcome compared to existing therapies is expected. Resistance to therapy, associated side effects, and the complexity of the diagnostic tests will continue to negatively impact the adoption of these therapies. These will be balanced against the potential benefit of the therapy. Negative reimbursement will also impact the therapy. Innovative development in oncology will increase market opportunities for MET-directed therapies. During the next three to five years, it will be critical for MET-directed therapies to demonstrate clinically meaningful improvement over existing therapies and address an unmet need.

List of C-MET & HGF Inhibitor Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies c-met & hgf inhibitor market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the c-met & hgf inhibitor market companies profiled in this report include-

  • Exelixis
  • Ipsen
  • Pfizer
  • Novartis
  • Takeda
  • Merck KGaA
  • Takeda Pharmaceutical

C-MET & HGF Inhibitor Market by Segment

The study includes a forecast for the global c-met & hgf inhibitor market by type, application, and region.

C-MET & HGF Inhibitor Market by Type [Value ($B) from 2019 to 2035]:

  • Cabozantinib
  • Crizotinib
  • Tepotinib
  • Others

C-MET & HGF Inhibitor Market by Application [Value ($B) from 2019 to 2035]:

  • Hospital
  • Drug Store

C-MET & HGF Inhibitor Market by Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the C-MET & HGF Inhibitor Market

A transition in the c-met & HGF inhibitor market has occurred from broad kinase inhibitors to antibody drug conjugates (ADCs) and biomarker-driven methods. 2025 was the year where numerous regulatory changes occurred for MET-amplified lung cancers. Various companies focused on developing companion diagnostics and partnering for MET inhibitors. Based on Lucintel's research, we expect changes in the market constant through 2027.

  • United States: In May 2025, the Food and Drug Administration (FDA) granted accelerated approval to AbbVie for the use of their antibody drug conjugate, Telisotuzumab Vedotin (Emrelis) for the treatment of non-squamous non-small-cell lung cancer (NSCLC). The FDA approved Emrelis based on the results from the Phase 2 study in which 42% of patients with the NSCLC tumour expressing high levels of c-Met achieved a partial response. With this approval, we anticipate more testing to identify lung cancers with c-Met overexpression.
  • China: In February 2025, AstraZeneca announced in their annual report that HUTCHMED's MET inhibitor, savolitinib (Orpathys) gained regulatory approval for the treatment of MET exon 14 skipping NSCLC. Additionally, AstraZeneca reported that savolitinib generated $100 million in global sales in 2024. As the drug is approved and commercially available in China, MET inhibitor research and clinical trials will help define China's role in biomarker-driven therapies.
  • Germany: Merck KGaA continued to advance the development of tepotinib and the companion diagnostics in Europe. The 2024 oncology pipeline of Merck KGaA contained multiple projects based on biomarker-driven approaches. The ongoing clinical and diagnostic projects in Germany provide a basis for the approval of anti-HGF/MET therapy in Europe.
  • India: Indian pharmaceutical companies continued to manufacture and market generic crizotinib through the country's controlled market for oncology products. The price-control policy of the Indian Department of Pharmaceuticals for over 350 essential drugs, including anti-cancer drugs, remained in place (January 2025). Over the next 3-5 years, it is expected that the manufacture and sale of generics of crizotinib will reduce the costs of MET inhibitor therapy and enhance its accessibility.
  • Japan: Both Merck KGaA and Taiho continued their efforts to gain market access and clinical adoption for anti-MET therapy in Japan. Tepotinib will be available in Japan for the treatment of MET Exon 14 skipped NSCLC. In the absence of a national health insurance coverage for anti-cancer therapies, the use of companion diagnostics will continue to facilitate and restrict the market access of anti-MET therapies through 2030.

Features of the Global C-MET & HGF Inhibitor Market

  • Market Size Estimates: C-MET & HGF inhibitor market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: C-MET & HGF inhibitor market size by type, application, and region in terms of value ($B).
  • Regional Analysis: C-MET & HGF inhibitor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the C-MET & HGF inhibitor market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the C-MET & HGF inhibitor market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the c-met & hgf inhibitor market by type (cabozantinib, crizotinib, tepotinib, and others), application (hospital and drug store), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global C-MET & HGF Inhibitor Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Cabozantinib : Trends and Forecast 2019 to 2035
  • 4.4 Crizotinib : Trends and Forecast 2019 to 2035
  • 4.5 Tepotinib : Trends and Forecast 2019 to 2035
  • 4.6 Others : Trends and Forecast 2019 to 2035

5. Global C-MET & HGF Inhibitor Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Hospital : Trends and Forecast 2019 to 2035
  • 5.4 Drug Store : Trends and Forecast 2019 to 2035

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global C-MET & HGF Inhibitor Market by Region

7. North American C-MET & HGF Inhibitor Market

  • 7.1 Overview
  • 7.2 North American C-MET & HGF Inhibitor Market by Type
  • 7.3 North American C-MET & HGF Inhibitor Market by Application
  • 7.4 The United States C-MET & HGF Inhibitor Market
  • 7.5 Canadian C-MET & HGF Inhibitor Market
  • 7.6 Mexican C-MET & HGF Inhibitor Market

8. European C-MET & HGF Inhibitor Market

  • 8.1 Overview
  • 8.2 European C-MET & HGF Inhibitor Market by Type
  • 8.3 European C-MET & HGF Inhibitor Market by Application
  • 8.4 German C-MET & HGF Inhibitor Market
  • 8.5 French C-MET & HGF Inhibitor Market
  • 8.6 Italian C-MET & HGF Inhibitor Market
  • 8.7 Spanish C-MET & HGF Inhibitor Market
  • 8.8 The United Kingdom C-MET & HGF Inhibitor Market

9. APAC C-MET & HGF Inhibitor Market

  • 9.1 Overview
  • 9.2 APAC C-MET & HGF Inhibitor Market by Type
  • 9.3 APAC C-MET & HGF Inhibitor Market by Application
  • 9.4 Chinese C-MET & HGF Inhibitor Market
  • 9.5 Indian C-MET & HGF Inhibitor Market
  • 9.6 Japanese C-MET & HGF Inhibitor Market
  • 9.7 South Korean C-MET & HGF Inhibitor Market
  • 9.8 Indonesian C-MET & HGF Inhibitor Market

10. ROW C-MET & HGF Inhibitor Market

  • 10.1 Overview
  • 10.2 ROW C-MET & HGF Inhibitor Market by Type
  • 10.3 ROW C-MET & HGF Inhibitor Market by Application
  • 10.4 Middle Eastern C-MET & HGF Inhibitor Market
  • 10.5 South American C-MET & HGF Inhibitor Market
  • 10.6 African C-MET & HGF Inhibitor Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunity by Type
    • 12.2.2 Growth Opportunity by Application
  • 12.3 Emerging Trends in the Global C-MET & HGF Inhibitor Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis Overview
  • 13.2 Exelixis
    • Company Overview
    • C-MET & HGF Inhibitor Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Ipsen
    • Company Overview
    • C-MET & HGF Inhibitor Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Pfizer
    • Company Overview
    • C-MET & HGF Inhibitor Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Novartis
    • Company Overview
    • C-MET & HGF Inhibitor Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Takeda
    • Company Overview
    • C-MET & HGF Inhibitor Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Merck KGaA
    • Company Overview
    • C-MET & HGF Inhibitor Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Takeda Pharmaceutical
    • Company Overview
    • C-MET & HGF Inhibitor Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global C-MET & HGF Inhibitor Market
  • Figure 2.1: Usage of C-MET & HGF Inhibitor Market
  • Figure 2.2: Classification of the Global C-MET & HGF Inhibitor Market
  • Figure 2.3: Supply Chain of the Global C-MET & HGF Inhibitor Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the C-MET & HGF Inhibitor Market
  • Figure 4.1: Global C-MET & HGF Inhibitor Market by Type in 2019, 2026, and 2035
  • Figure 4.2: Trends of the Global C-MET & HGF Inhibitor Market ($B) by Type
  • Figure 4.3: Forecast for the Global C-MET & HGF Inhibitor Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Cabozantinib in the Global C-MET & HGF Inhibitor Market (2019-2035)
  • Figure 4.5: Trends and Forecast for Crizotinib in the Global C-MET & HGF Inhibitor Market (2019-2035)
  • Figure 4.6: Trends and Forecast for Tepotinib in the Global C-MET & HGF Inhibitor Market (2019-2035)
  • Figure 4.7: Trends and Forecast for Others in the Global C-MET & HGF Inhibitor Market (2019-2035)
  • Figure 5.1: Global C-MET & HGF Inhibitor Market by Application in 2019, 2026, and 2035
  • Figure 5.2: Trends of the Global C-MET & HGF Inhibitor Market ($B) by Application
  • Figure 5.3: Forecast for the Global C-MET & HGF Inhibitor Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Hospital in the Global C-MET & HGF Inhibitor Market (2019-2035)
  • Figure 5.5: Trends and Forecast for Drug Store in the Global C-MET & HGF Inhibitor Market (2019-2035)
  • Figure 6.1: Trends of the Global C-MET & HGF Inhibitor Market ($B) by Region (2019-2026)
  • Figure 6.2: Forecast for the Global C-MET & HGF Inhibitor Market ($B) by Region (2027-2035)
  • Figure 7.1: Trends and Forecast for the North American C-MET & HGF Inhibitor Market (2019-2035)
  • Figure 7.2: North American C-MET & HGF Inhibitor Market by Type in 2019, 2026, and 2035
  • Figure 7.3: Trends of the North American C-MET & HGF Inhibitor Market ($B) by Type (2019-2026)
  • Figure 7.4: Forecast for the North American C-MET & HGF Inhibitor Market ($B) by Type (2027-2035)
  • Figure 7.5: North American C-MET & HGF Inhibitor Market by Application in 2019, 2026, and 2035
  • Figure 7.6: Trends of the North American C-MET & HGF Inhibitor Market ($B) by Application (2019-2026)
  • Figure 7.7: Forecast for the North American C-MET & HGF Inhibitor Market ($B) by Application (2027-2035)
  • Figure 7.8: Trends and Forecast for the United States C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 7.9: Trends and Forecast for the Mexican C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 7.10: Trends and Forecast for the Canadian C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 8.1: Trends and Forecast for the European C-MET & HGF Inhibitor Market (2019-2035)
  • Figure 8.2: European C-MET & HGF Inhibitor Market by Type in 2019, 2026, and 2035
  • Figure 8.3: Trends of the European C-MET & HGF Inhibitor Market ($B) by Type (2019-2026)
  • Figure 8.4: Forecast for the European C-MET & HGF Inhibitor Market ($B) by Type (2027-2035)
  • Figure 8.5: European C-MET & HGF Inhibitor Market by Application in 2019, 2026, and 2035
  • Figure 8.6: Trends of the European C-MET & HGF Inhibitor Market ($B) by Application (2019-2026)
  • Figure 8.7: Forecast for the European C-MET & HGF Inhibitor Market ($B) by Application (2027-2035)
  • Figure 8.8: Trends and Forecast for the German C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 8.9: Trends and Forecast for the French C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 8.10: Trends and Forecast for the Spanish C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 8.11: Trends and Forecast for the Italian C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 8.12: Trends and Forecast for the United Kingdom C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 9.1: Trends and Forecast for the APAC C-MET & HGF Inhibitor Market (2019-2035)
  • Figure 9.2: APAC C-MET & HGF Inhibitor Market by Type in 2019, 2026, and 2035
  • Figure 9.3: Trends of the APAC C-MET & HGF Inhibitor Market ($B) by Type (2019-2026)
  • Figure 9.4: Forecast for the APAC C-MET & HGF Inhibitor Market ($B) by Type (2027-2035)
  • Figure 9.5: APAC C-MET & HGF Inhibitor Market by Application in 2019, 2026, and 2035
  • Figure 9.6: Trends of the APAC C-MET & HGF Inhibitor Market ($B) by Application (2019-2026)
  • Figure 9.7: Forecast for the APAC C-MET & HGF Inhibitor Market ($B) by Application (2027-2035)
  • Figure 9.8: Trends and Forecast for the Japanese C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 9.9: Trends and Forecast for the Indian C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 9.10: Trends and Forecast for the Chinese C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 9.11: Trends and Forecast for the South Korean C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 9.12: Trends and Forecast for the Indonesian C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 10.1: Trends and Forecast for the ROW C-MET & HGF Inhibitor Market (2019-2035)
  • Figure 10.2: ROW C-MET & HGF Inhibitor Market by Type in 2019, 2026, and 2035
  • Figure 10.3: Trends of the ROW C-MET & HGF Inhibitor Market ($B) by Type (2019-2026)
  • Figure 10.4: Forecast for the ROW C-MET & HGF Inhibitor Market ($B) by Type (2027-2035)
  • Figure 10.5: ROW C-MET & HGF Inhibitor Market by Application in 2019, 2026, and 2035
  • Figure 10.6: Trends of the ROW C-MET & HGF Inhibitor Market ($B) by Application (2019-2026)
  • Figure 10.7: Forecast for the ROW C-MET & HGF Inhibitor Market ($B) by Application (2027-2035)
  • Figure 10.8: Trends and Forecast for the Middle Eastern C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 10.9: Trends and Forecast for the South American C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 10.10: Trends and Forecast for the African C-MET & HGF Inhibitor Market ($B) (2019-2035)
  • Figure 11.1: Porter's Five Forces Analysis of the Global C-MET & HGF Inhibitor Market
  • Figure 11.2: Market Share (%) of Top Players in the Global C-MET & HGF Inhibitor Market (2026)
  • Figure 12.1: Growth Opportunities for the Global C-MET & HGF Inhibitor Market by Type
  • Figure 12.2: Growth Opportunities for the Global C-MET & HGF Inhibitor Market by Application
  • Figure 12.3: Growth Opportunities for the Global C-MET & HGF Inhibitor Market by Region
  • Figure 12.4: Emerging Trends in the Global C-MET & HGF Inhibitor Market

List of Tables

  • Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the C-MET & HGF Inhibitor Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the C-MET & HGF Inhibitor Market by Region
  • Table 1.3: Global C-MET & HGF Inhibitor Market Parameters and Attributes
  • Table 3.1: Trends of the Global C-MET & HGF Inhibitor Market (2019-2026)
  • Table 3.2: Forecast for the Global C-MET & HGF Inhibitor Market (2027-2035)
  • Table 4.1: Attractiveness Analysis for the Global C-MET & HGF Inhibitor Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global C-MET & HGF Inhibitor Market (2019-2026)
  • Table 4.3: Market Size and CAGR of Various Type in the Global C-MET & HGF Inhibitor Market (2027-2035)
  • Table 4.4: Trends of Cabozantinib in the Global C-MET & HGF Inhibitor Market (2019-2026)
  • Table 4.5: Forecast for Cabozantinib in the Global C-MET & HGF Inhibitor Market (2027-2035)
  • Table 4.6: Trends of Crizotinib in the Global C-MET & HGF Inhibitor Market (2019-2026)
  • Table 4.7: Forecast for Crizotinib in the Global C-MET & HGF Inhibitor Market (2027-2035)
  • Table 4.8: Trends of Tepotinib in the Global C-MET & HGF Inhibitor Market (2019-2026)
  • Table 4.9: Forecast for Tepotinib in the Global C-MET & HGF Inhibitor Market (2027-2035)
  • Table 4.10: Trends of Others in the Global C-MET & HGF Inhibitor Market (2019-2026)
  • Table 4.11: Forecast for Others in the Global C-MET & HGF Inhibitor Market (2027-2035)
  • Table 5.1: Attractiveness Analysis for the Global C-MET & HGF Inhibitor Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global C-MET & HGF Inhibitor Market (2019-2026)
  • Table 5.3: Market Size and CAGR of Various Application in the Global C-MET & HGF Inhibitor Market (2027-2035)
  • Table 5.4: Trends of Hospital in the Global C-MET & HGF Inhibitor Market (2019-2026)
  • Table 5.5: Forecast for Hospital in the Global C-MET & HGF Inhibitor Market (2027-2035)
  • Table 5.6: Trends of Drug Store in the Global C-MET & HGF Inhibitor Market (2019-2026)
  • Table 5.7: Forecast for Drug Store in the Global C-MET & HGF Inhibitor Market (2027-2035)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global C-MET & HGF Inhibitor Market (2019-2026)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global C-MET & HGF Inhibitor Market (2027-2035)
  • Table 7.1: Trends of the North American C-MET & HGF Inhibitor Market (2019-2026)
  • Table 7.2: Forecast for the North American C-MET & HGF Inhibitor Market (2027-2035)
  • Table 7.3: Market Size and CAGR of Various Type in the North American C-MET & HGF Inhibitor Market (2019-2026)
  • Table 7.4: Market Size and CAGR of Various Type in the North American C-MET & HGF Inhibitor Market (2027-2035)
  • Table 7.5: Market Size and CAGR of Various Application in the North American C-MET & HGF Inhibitor Market (2019-2026)
  • Table 7.6: Market Size and CAGR of Various Application in the North American C-MET & HGF Inhibitor Market (2027-2035)
  • Table 7.7: Trends and Forecast for the United States C-MET & HGF Inhibitor Market (2019-2035)
  • Table 7.8: Trends and Forecast for the Mexican C-MET & HGF Inhibitor Market (2019-2035)
  • Table 7.9: Trends and Forecast for the Canadian C-MET & HGF Inhibitor Market (2019-2035)
  • Table 8.1: Trends of the European C-MET & HGF Inhibitor Market (2019-2026)
  • Table 8.2: Forecast for the European C-MET & HGF Inhibitor Market (2027-2035)
  • Table 8.3: Market Size and CAGR of Various Type in the European C-MET & HGF Inhibitor Market (2019-2026)
  • Table 8.4: Market Size and CAGR of Various Type in the European C-MET & HGF Inhibitor Market (2027-2035)
  • Table 8.5: Market Size and CAGR of Various Application in the European C-MET & HGF Inhibitor Market (2019-2026)
  • Table 8.6: Market Size and CAGR of Various Application in the European C-MET & HGF Inhibitor Market (2027-2035)
  • Table 8.7: Trends and Forecast for the German C-MET & HGF Inhibitor Market (2019-2035)
  • Table 8.8: Trends and Forecast for the French C-MET & HGF Inhibitor Market (2019-2035)
  • Table 8.9: Trends and Forecast for the Spanish C-MET & HGF Inhibitor Market (2019-2035)
  • Table 8.10: Trends and Forecast for the Italian C-MET & HGF Inhibitor Market (2019-2035)
  • Table 8.11: Trends and Forecast for the United Kingdom C-MET & HGF Inhibitor Market (2019-2035)
  • Table 9.1: Trends of the APAC C-MET & HGF Inhibitor Market (2019-2026)
  • Table 9.2: Forecast for the APAC C-MET & HGF Inhibitor Market (2027-2035)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC C-MET & HGF Inhibitor Market (2019-2026)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC C-MET & HGF Inhibitor Market (2027-2035)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC C-MET & HGF Inhibitor Market (2019-2026)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC C-MET & HGF Inhibitor Market (2027-2035)
  • Table 9.7: Trends and Forecast for the Japanese C-MET & HGF Inhibitor Market (2019-2035)
  • Table 9.8: Trends and Forecast for the Indian C-MET & HGF Inhibitor Market (2019-2035)
  • Table 9.9: Trends and Forecast for the Chinese C-MET & HGF Inhibitor Market (2019-2035)
  • Table 9.10: Trends and Forecast for the South Korean C-MET & HGF Inhibitor Market (2019-2035)
  • Table 9.11: Trends and Forecast for the Indonesian C-MET & HGF Inhibitor Market (2019-2035)
  • Table 10.1: Trends of the ROW C-MET & HGF Inhibitor Market (2019-2026)
  • Table 10.2: Forecast for the ROW C-MET & HGF Inhibitor Market (2027-2035)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW C-MET & HGF Inhibitor Market (2019-2026)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW C-MET & HGF Inhibitor Market (2027-2035)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW C-MET & HGF Inhibitor Market (2019-2026)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW C-MET & HGF Inhibitor Market (2027-2035)
  • Table 10.7: Trends and Forecast for the Middle Eastern C-MET & HGF Inhibitor Market (2019-2035)
  • Table 10.8: Trends and Forecast for the South American C-MET & HGF Inhibitor Market (2019-2035)
  • Table 10.9: Trends and Forecast for the African C-MET & HGF Inhibitor Market (2019-2035)
  • Table 11.1: Product Mapping of C-MET & HGF Inhibitor Suppliers Based on Segments
  • Table 11.2: Operational Integration of C-MET & HGF Inhibitor Manufacturers
  • Table 11.3: Rankings of Suppliers Based on C-MET & HGF Inhibitor Revenue
  • Table 12.1: New Product Launches by Major C-MET & HGF Inhibitor Producers (2019-2026)
  • Table 12.2: Certification Acquired by Major Competitor in the Global C-MET & HGF Inhibitor Market